Wealth Alliance LLC bought a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,128 shares of the company's stock, valued at approximately $277,000.
A number of other large investors also recently bought and sold shares of the stock. Marotta Asset Management lifted its position in Genmab A/S by 5.8% in the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock valued at $265,000 after buying an additional 739 shares during the last quarter. Laird Norton Wetherby Wealth Management LLC increased its stake in Genmab A/S by 17.3% during the fourth quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company's stock worth $286,000 after purchasing an additional 2,023 shares during the period. NewEdge Advisors LLC increased its stake in Genmab A/S by 12.7% during the fourth quarter. NewEdge Advisors LLC now owns 19,304 shares of the company's stock worth $403,000 after purchasing an additional 2,171 shares during the period. Barclays PLC increased its stake in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Genmab A/S during the fourth quarter worth about $60,000. Institutional investors and hedge funds own 7.07% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on GMAB. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Wall Street Zen lowered shares of Genmab A/S from a "buy" rating to a "hold" rating in a research note on Sunday, July 20th. HC Wainwright reiterated a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus target price of $37.80.
Read Our Latest Analysis on GMAB
Genmab A/S Price Performance
Shares of GMAB stock traded down $0.23 during trading hours on Friday, reaching $23.40. 713,820 shares of the stock were exchanged, compared to its average volume of 1,079,586. The business's fifty day moving average is $21.49 and its two-hundred day moving average is $20.81. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $28.56. The firm has a market capitalization of $15.01 billion, a P/E ratio of 13.30, a P/E/G ratio of 7.11 and a beta of 0.94.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. As a group, equities research analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.
About Genmab A/S
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access